PharmExec Blog
Follow Us
RSS
Bookstore
Author Archives: Patrick Clinton
Valeant to Lay Off Half Its Workforce
The last time Pharm Exec covered Valeant Pharmaceuticals, it was in 2005, and things were looking good for the company. It had a new name, and a sleek new organization, lighter than the old by 8,000 employees. New CEO Timothy Tyson had created a talented and enthusiastic new management team. A new strategy was in [...]
Posted in Strategy Leave a comment
Millennium Founder Heads a New Biotech
If, in the wake of the sale of Millennium, you’ve been wondering what ever happened to the company’s co-founder and longtime CEO Mark Levin, the answer was in this morning’s deal news, in the announcement that a young biotech called Constellation Pharmaceuticals had closed a $32 million Series A financing. The companies coming up with [...]
Secrets of the Dealmakers Revealed . . .
I had a chance late last week to moderate a panel at the Healthcare Dealmaking Symposium, sponsored by our friends at The Deal. My panelists, Annarie Lyles, SVP and Head of Corporate Development for Genmab, and Robert Knowles, Senior Director of Worldwide Business Development for Pfizer, had some very interesting insights into the state of [...]
Posted in Deals Leave a comment
Preemption Watch: Legal Eagle Explains Riegel
The Supreme Court last Wednesday decided the first of an important series of cases having to do with whether FDA approval and regulation preempts lawsuits at the state level. The case was Riegel v. Medtronic, and it had to do with a balloon catheter that burst during an angioplasty. Though it’s a device case, not [...]
Posted in Legal, Regulatory Leave a comment
The DTC Hearings: Gleaning Some Nuggets